Drug Profile

Lenacapavir pacfosacil - Gilead Sciences

Alternative Names: GS-4182

Latest Information Update: 09 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gilead Sciences
Class Antiretrovirals
Mechanism of Action Capsid protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II/III HIV-1 infections

Most Recent Events

16 Mar 2026 Gilead Sciences terminates phase II/III WONDERS 2 trial in HIV-1 infections (Combination therapy, Treatment-naive) in USA, Spain, South Africa, Romania, Puerto Rico, Portugal, Poland, Germany, Canada (PO) due to sponsor decision (NCT06613685)
10 Jun 2025 US FDA places clinical hold on HIV treatment trials of GS 1720 and GS 4182
21 Oct 2024 Phase-II/III clinical trials in HIV-1 infections (Combination therapy, Treatment-naive) in USA (PO) (NCT06613685)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com